Human anti-animal antibody interferences in immunological assays

Clinical Chemistry

Volumn 45, Issue 7, 1999, Pages 942-956

  Kricka, Larry J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANALYTICAL ERROR; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CROSS REACTION; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; IMMUNORADIOMETRIC ASSAY; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BODY FLUIDS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOASSAY; MICE;

ANIMALIA; CAPRA HIRCUS; EQUUS CABALLUS; ORYCTOLAGUS CUNICULUS; OVIS ARIES; SUS SCROFA;

EID: 0032814344     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Ammann AJ, Hong R. Anti-antiserum antibody as a cause of double precipitin rings in immunoglobulin quantitation and its relation to milk precipitins. J Immunol 1971;106:567-9.
2. Miller J, Levinson S. Interference in immunoassays. In: Diamandis EP, Christopoulos TP, eds. Immunoassay. San Diego: Academic Press, 1997:165-90.
3. Levinson SS. Antibody multispecificity in immunoassay interference. Clin Biochem 1992;25:77-87.
4. Prince AM, Brotman B, Jass D, Ikram H. Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis B antigen. Lancet 1973;1:1346-50.
5. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32:1491-5.
6. Boscato LM, Stuart MC. Haterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34:27-33.
7. Hollinger FB. Radioimmunoassay for detection of hepatitis-associated antigen (HBAg). In: Vycis GN, Hawkins HA, Schmid R, ads. Hepatitis and blood transfusion. New York; Grune and Strattton, 1972;167-70.
8. Kohse KP, Wisser H. Antibodies as a source of analytical errors. J Clin Chem Clin Biochem 1990;28:881-92.
9. Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981;58:78-86.
10. Rothenberg RM, Farr RS. Anti-bovine serum albumin and anti-αlactalbumin in the serum of children and adults. Pediatrics 1965;35:571-88.
11. Nores GA, Dennis RD, Helling F, Wiegandt H. Human heterophile antibodies recognizing epitopes present on insect glycolipids. J Biochem 1991;110:1-8.
12. Akinwolere OA, Williams AI. Immunity in malaria. II. Heterophile and malarial antibodies in acute Plasmodium falciparum infection. Afr J Med Sci 1989;18:235-40.
13. Nishimaki T, Kano K, Milgrom F. Studies on heterophile antibodies in rheumatoid arthritis. Arthritis Rheum 1978;21:634-8.
14. Kakoma I, Mwendapole RM, Bulsara M, Mabenga S, Syabula CS, Wurapa FK. Profiles of heterophile antibody to various mammalian erythrocytes in rural populations of Zambia. Comp Immunol Microbiol Infect Dis 1987;10:51-7.
15. Satoh PS, Elberg AJ, Fleming WE, Baluarte HJ, Gruskin AB. Heterophile antibodies in the serum of children with nephrotic syndrome. Vox Sang 1980;39:128-33.
16. Parratt D, Cobb SJ. Heterophile antibody to red cells in human trypanosomiasis. Afr J Med Med Sci 1978;7:57-64.
17. Suzuki E, Naiki M. Heterophile antibodies to rabbit erythrocytes in human sera and identification of the antigen as a glycolipid. J Biochem 1984;95:103-8.
18. Tamura T, Kano K, Milgrom F. Specificity of transplantation heterophile antibodies. Transplantation 1984;37:475-8.
19. US Department of Health and Social Services. Food and Drug Administration. Review criteria for assessment of professional use human chorionic gonadotropin (hCG) in vitro diagnostic devices (IVDs). Washington, DC: Department of Health and Social Service, 1996.
20. US Department of Health and Social Services. Review criteria for assessment of rheumatoid factor (RF) in vitro diagnostic devices using enzyme-linked immunosssay (EIA), enzyme linked immunosorbent assay (ELISA), particle agglutination tests, and laser and rate nephelometry. Washington, DC: Department of Health and Social Services, 1997.
21. Itoh Y, Yamaguchi T. Factors that affect analytical results in an enzyme immunoassay. Nippon Rinsho Jpn J Clin Mad 1995;53:2143-8.
22. Van Kroonenburgh MJ, Pauwels EK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 1988;9:919-30.
23. Grossman HB. Clinical applications of monoclonal antibody technology. Urol Clin Am 1986;13:465-74.
24. Kuus-Reichel K, Grauer LS, Karavodln LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1994;1:365-72.
25. Gilbert C. Clinical uses of anti-thymocyto globulin (ATGAM). Part I. N C Med J 1984;45:737-9.
26. Belitsky P, MacDonald AS, Lawen J, McAlister V, Bitter-Suermann H, Kiberd B. Use of rabbit anti-thymocyte globulin for induction immunosuppression in high-risk kidney transplant recipients. Transplant Proc 1997;29:16S-17S.
27. Ameno S, Ameno K, Fuke C, Kiryu T, Ijiri I. IgG subclass distributions of anti-horse serum antibodies and natural venomantibodies produced in response to antivenom injection or snake bite in humans. Toxicon 1990;28:347-50.
28. Plosker GL, McTavish D. Intranasel salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996;8:378-400.
29. Azrin MA. The use of antibodies in clinical cardiology. Am Heart J 1992;124:753-68.
30. Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, et al. Safety profile of porcine factor VIII and Its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996;75:25-9.
31. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16(Suppl 3):155-65.
32. Padova G, Briguglia G, Tita P, Munguira ME, Arpi ML, Pezzino V. Hypergonadotropinemia not associated to ovarian failure and induced by factors interfering in radioimmunoassay. Fertil Steril 1991;55:637-9.
33. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997;176(Suppl 1):S20-3.
34. Schaison G, Thomopoulos P, Moulias R, Feinstein MC. False hyperthyrotropinemia induced by heterophilic antibodies against rabbit serum. J Clin Endocrinol Metab 1981;53:200-2.
35. Smid WM, van der Meer J. Five-year follow-up of human antimouse antibody in multitransfused HIV negative haemophilics treated with a monoclonal purified plasma derived factor VIII concentrate [Letter]. Thromb Haemost 1995;74:1203.
36. Hawkins BR, Saueracker GC, Dawkins RL, Davey MG, O'Connor KJ. Population study of heterophile antibodies. Vox Sang 1980;39:339-42.
37. Larsson A, Hedenborg G, Carlstrom A. Placental transfer of maternal anti-rabbit IgG causing falsely elevated TSH levels in neonates. Acta Paediatr Scand 1981;70:699-703.
38. Czernichow P, Van Dalem JL, Hennen G. Transient neonatal hyperthyrotropinemia: a factitious syndrome due to the presence of heterophilic antibodies in the plasma of infants and their mothers. J Clin Endocrinol Metab 1981;53:387-93.
39. Berglund L, Holmberg NG. Heterophilic antibodies against rabbit serum causing falsely elevated gonadotropin levels. Acta Obstet Gynecol Scand 1989;68:377-8.
40. Jewell DP, Truelove SC. Circulating antibodies to cow's milk proteins in ulcerative colitis. Gut 1972;13:796-801.
41. Falchuck KR, Iselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease: characterization of the antibody response. Gastroenterology 1976;70:5-8.
42. Fukuta S, Yamakawa K, Hayashi Y, Iwamoto S, Umemoto S, Kusukawa R, Wada K. Immunological study of heart diseases with special reference to the cytotoxicity of the heterophile antibody against cultured myocardial cells. Jpn Circ J 1984;48:1354-7.
43. Wijdenes J, Roy C, Morel-Fourrier B, Racadot E. Monoclonal antibodies in human organ transplantation and auto-immune diseases. Therapie 1992;47:283-7.
44. Bischof Delaloye A, Delaloye B. Diagnostic applications and therapeutic approaches with different preparations of anti-CEA antibodies. Int J Biol Markers 1992;7:193-7.
45. Greiner JW, Guadagni F, Hand PH, Pestka S, Noguchi P, Fisher PB, Schlom J. Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas. Cancer Treat Res 1990;51:413-32.
46. Hoffman T. Anticipating, recognizing, and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti-mouse antibodies. Cancer Res 1990;50:1049s-50s.
47. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-400.
48. Diliman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994;12:1497-515.
49. Ballow M, Nelson R. Immunopharmacology: immunomodulation and immunotherapy [Review]. JAMA 1997;278:2008-17.
50. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994;98:323-9.
51. Carey G, Lisi PJ, Schroeder TJ. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 1995;60:151-8.
52. O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, et al. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss. J Heart Lung Transplant 1991;10:217-21.
53. Hammond EA, Yowell RL, Greenwood J, Hartung L, Renlund D, Wittwer C. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. Transplantation 1993;55:1061-3.
54. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992;79:576-85.
55. 99 mTc-BW 4): initial clinical results. Nuklearmedizin 1993;32:178-82.
56. Lind P, Langsteger W, Koltringer P, Dimai HP, Passl R, Eber O. Immunoscintigraphy of inflammatory processes with a technetium-99 m-labeled monoclonal antigranulocyte antibody (MAb BW 250/183). J Nucl Med 1990;31:417-23.
57. Lind P, Lechner P, Arian-Schad K, Klimpfinger M, Cesnik H, Kammerhuber F, Eber O. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99 m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991;32:1319-25.
58. Buchler M, Friess H, Malfertheiner P, Schultheiss KH, Muhrer KH, Kraemer HP, Beger HG. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990;7:151-7.
59. Buchler M, Kubel R, Malfertheiner P, Friess H, Schulz G, Bosslet K, Beger HG. Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494. Dtsch Med Wochenschr 1988;113:374-80.
60. Abdel-Nabi HH, Levine G, Lamki LM, Murray JL, Tauxe WN, Shah AN, et al. Colorectal carcinoma metastases: detection with In-111-labeled monoclonal antibody CCR 086. Radiology 1990;176:117-22.
61. Lazarovits AI, Tibbles LA, Grant DR, Ghent CN, Wall WJ, White MJ, Joncas JH. Anti-B cell antibodies for the treatment of monoclonal Epstein-Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation. Clin Investig Med 1994;17:621-5.
62. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32A:636-40.
63. Moffat FL Jr, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99 m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14:2295-305.
64. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-64.
65. DeNardo GL, Lamborn KR, DeNardo SJ, Goldstein DS, Dolber-Smith EG, Kroger LA, et al. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Res 1995;55(Suppl):5893s-8s.
66. Juweid M, Sharkey RM, Behr TM, Swayne LC, Dunn R, Ying Z, et al. Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2. Cancer 1996;78:157-68.
67. Lamki LM, Zukiwski AA, Shanken LJ, Legha SS, Benjamin RS, Plager CE, et al. Radioimaging of melanoma using 99 mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Res 1990;50(Suppl):904s-8s.
68. Scheinberg D, Straus D, Yeh SD, Divgi C, Garin-Chesa P, Graham M, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990;8:792-803.
69. Harkonen S, Scannon P, Mischak RP, Spitler LE, Foxall C, Kennedy D, Greenberg R. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother 1988;32:710-6.
70. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-93.
71. Tjandra JJ, Pietersz GA, Teh JG, Cuthbertson AM, Sullivan JR, Penfold C, et al. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report. Surgery 1989;106:533-45.
72. Goodman GE, Beaumier P, Hellstrom I, Fernyhough B, Hellstrom KE. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985;3:340-52.
73. Goldberg LC, Bradley JA, Connolly J, Friend PJ, Oliveira DB, Parrott NR, et al. Anti-CD45 monoclonal antibody perfusion of human renal allografts prior to transplantation. A safety and immunohistological study. CD45 Study Group. Transplantation 1995;59:1285-93.
74. Blaise D, Olive D, Hirn M, Viens P, Lafage M, Attal M, et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 1991;8:105-11.
75. Kirby AJ. The potential of catalytic antibodies. Acta Chem Scand 1996;50:203-10.
76. McCarthy RC. Interference in immunoenzymometric assays caused by IgM anti-mouse IgG antibodies. Arch Pathol Lab Med 1988;112:901-7.
77. Iitaka M, Ishii N, Ishikawa N, Yoshimura H, Momotani N, Saitou H, Ito K. A case of Graves' disease with false hyperthyrotropinemia who developed silent thyroiditis. Endocrinol Jpn 1991;38:667-71.
78. Frodin JE, Lefvert AK, Mollstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 1992;21:153-65.
79. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986;137:830-8.
80. Reinsberg J. Interference by human antibodies with tumor marker assays. Hybridoma 1995;14:205-8.
81. Buist MR, Kenemans P, van Kamp GJ, Haisma HJ. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995;40:24-30.
82. van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Wamaar SO, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Investig 1996;98:1441-8.
83. Moseley KR, Knapp RC, Haisma HJ. An assay for the detection of human anti-murine immunoglobulins in the presence of CA125 antigen. J Immunol Methods 1988;106:1-6.
84. Ledermann JA, Begent RH, Bagshawe KD, Riggs SJ, Searle F, Glaser MG, et al. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 1988;58:654-7.
85. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992;21:109-20.
86. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73(Suppl):1121-5.
87. Lipp RW, Passath A, Leb G. The incidence of non-iatrogenic human anti-mouse antibodies and their possible clinical relevance [Letter]. Eur J Nucl Med 1991;18:996-7.
88. Mossner E, Lenz H, Bienhaus G. Elimination of heterophilic antibody interference in monoclonal sandwich tests. Clin Chem 1990;36:1093.
89. Thompson RJ, Jackson AP, Langiois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects - incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin Chem 1986;32:476-81.
90. Hedenborg G, Pettersson T, Carlstrom A. Heterophilic antibodies causing falsely raised thyroid-stimulating hormone result [Letter]. Lancet 1979;ii:755.
91. Larsson A, Mellstedt H. Chicken antibodies: a tool to avoid interference by human anti-mouse antibodies in ELISA after in vivo treatment with murine monoclonal antibodies. Hybridoma 1992;11:33-8.
92. Falchuk KR, Isselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Gastroenterology 1976;70:5-8.
93. Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobulins in healthy subjects: a hazard for immunoassay [Letter]. Lancet 1980;ii:1136.
94. Toft JC, Tromholt N. Production of human antimurine antibody after in vivo use of radioisotope labelled murine antibodies. Ugeskr Laeg 1991;153:2813-5.
95. 99 mTc-labeled CEA antibody. Nuklearmedizin 1994;33:127-8.
96. 99 mTc-anti-CEA radio-immunoscintigraphy of lung adenocarcinoma. Chest 1991;99:14-9.
97. Dillman RO, Beauregard JC, Halpern SE, Clutter M. Toxicities and side effects associated with intravenous infusion of murine monoclonal antibodies. J Biol Response Modif 1986;5:73-84.
98. Torres G, Berna L, Estorch M, Juarez C, Martinez-Duncker D, Carrio I. Pre-existing human anti-murine antibodies and the effect of immune complexes on the outcome of immunoscintigraphy. Clin Nucl Med 1993;18:477-81.
99. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, et al. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol 1997;17:96-106.
100. Quan WD Jr, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, Mitchell MS. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 1997;15:2103-10.
101. US Department of Health and Social Services. Food and Drug Administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Docket no. 94D-0259. Washington, DC: Department of Health and Social Services, 1997.
102. Bouvier JF, Pernod J, Rivoire M, Maiassi N. Serum levels of tumor markers and presence of human antimouse antibodies: implications for diagnosis and treatment with radiolabeled monoclonal antibodies. Cancer Detect Prev 1988;13:251-62.
103. Reinsberg J, Schmolling Ackermann D. A simple and sensitive assay for determination of human anti-idiotypic anti-B72.3 antibodies, which is not affected by the presence of tumour-associated glycoprotein 72. Eur J Clin Chem Clin Biochem 1996;34:237-44.
104. Hewitt J, Burton IE. Incidence of autoantibodies to GPIIb/IIIa in chronic autoimmune thrombocytopenic purpura may be overestimated by the MAIPA. Br J Haematol 1994;86:418-20.
105. Tjandra JJ, Ramzdi L, McKenzie IFC. Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 1990;68:367-76,
106. HAMA Survey Group. Interlaboratory survey of methods for measuring human anti-mouse antibodies. Clin Chem 1992;38:172-3.
107. HAMA Survey Group. Survey of methods for measuring human anti-mouse antibodies. Clin Chim Acta 1993;215:153-63.
108. Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transplant Immunol 1995;3:212-21.
109. Seccamani E, Tattanelli M, Mariani M, Spranzi E, Scassellati GA, Siccardi AG. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Radiat Appl Instrum Part B 1989;16:167-70.
110. 2 monoclonal antibody to patients with ovarian cancer. J Nucl Med 1992;33:1958-63.
111. Kricka LK, Nozaki O, Goodman DBP, Ji X. Simple qualitative immunoassay of human anti-mouse antibodies evaluated. Clin Chem 1992;38:2558-60.
112. Turpeinen U, Lehtovirta P, Stenman UH. CA 125 determined by three methods in samples from patients with human anti-mouse antibodies (HAMA). Clin Chem 1995;41:1667-9.
113. Thomas CM, Massuger LF, Segers MF, Schijf CP, Doesburg WH, Wobbes T. Analytical and clinical performance of improved Abbott IMx CA 125 assay: comparison with Abbott CA 125 RIA. Clin Chem 1995;41:211-6.
114. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993;39:2509-13.
115. 2 fragments of OC125 antibody. Clin Chem 1993;39:891-6.
116. De Jager R, Abdei-Nabi H, Serafini A, Pecking A, Klein JL, Hanna MG Jr. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med 1993;23:165-79.
117. Turpeinen U, Lehtovirta P, Alfthan H, Stenman UH. Interference by human anti-mouse antibodies in CA 125 assay after immunoscintigraphy: anti-idiotypic antibodies not neutralized by mouse IgG but removed by chromatography. Clin Chem 1990;36:1333-8.
118. Boerman OC, Segers MF, Poels LG, Kenemans P, Thomas CM. Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 1990;36:888-91.
119. Reinsberg J, Heydweiller A, Wagner U, Pfeil K, Oehr P, Krebs D. Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection. Clin Chem 1990;36:164-7.
120. 2 fragments of the OC125 antibody. Eur J Clin Chem Clin Biochem 1993;31:323-7.
121. Morton BA, O'Connor-Treasel M, Beatty BG, Shively JE, Beatty JD. Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 1988;123:1242-6.
122. Ferroni P, Milenic DE, Roselli M, Carrasquillo JA, Raubitschek A, Schlom J, Colcher D. Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols. Int J Biol Markers 1990;5:166-76.
123. Kuroki M, Matsumoto Y, Arakawa F, Haruno M, Murakami M, Kuwahara M, et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J Immunol Methods 1995;180:81-91.
124. Price MR, Sekowski M, Yang GY, Durrant LG, Robins RA, Baldwin RW. Reactivity of an anti-(human gastric carcinoma) monoclonal antibody with core-related peptides of gastrointestinal mucin. Cancer Immunol Immunother 1991;33:80-4.
125. Kricka LJ, Schmerfeld-Pruss D, Senior M, Goodman DB, Kaladas P. Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 1990;36:892-4.
126. 2 conjugate and polyclonal mouse IgG. Clin Chem 1992;38:1737-42.
127. Murthy VV, Karmen A. Activity concentration and mass concentration (monoclonal antibody immunoenzymometric method) compared for creatine kinase MB isoenzyme in serum. Clin Chem 1986;32:1956-9.
128. Deacon R, Hellebostad M, Gaines Das RE, Milne A, Rowley M, Cotes PM. Invalidity from nonparallelism in a radioimmunoassay for erythropoietin accounted for by human serum antibodies to rabbit IgG. Exp Hematol 1993;21:1680-5.
129. Check JH, Ubelacker L, Lauer CC. Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Gynecol Obstet Investig 1995;40:139-40.
130. Flad TM, Duffy J, McKenna TJ. Multiple spuriously abnormal thyroid function indices due to heterophilic antibodies. Clin Endocrinol 1994;41:391-5.
131. Padova G, Briguglia G, Tita P, Munguira ME, Arpi ML, Pezzino V. Hypergonadotropinemia not associated to ovarian failure and induced by factors interfering in radioimmunoassay. Fertil Steril 1991;55:637-9.
132. Jockenhovel F, Khan SA, Nieschlag E. Circulating antibodies to monoclonal immunoglobulins used in a follitropin assay may cause incorrect fertility diagnosis. J Clin Chem Clin Biochem 1989;27:825-8.
133. Check JH, Nowroozi K, Chase JS, Lauer C, Elkins B, Wu CH. False-positive human chorionic gonadotropin levels caused by a heterophile antibody with the immunoradiometric assay. Am J Obstet Gynecol 1988;158:99-100.
134. Pardue MG, Taylor EH, London S, Walls RC, Pappas AA. Clinical comparison of immunoradiometric assays for intact versus β-specific human chorionic gonadotropin. Am J Clin Pathol 1990;93:347-51.
135. Letterie GS, Rose S, Miyazawa K. Heterophile antibodies and false-positive assays for human chorionic gonadotropin. Am J Obstet Gynecol 1988;159:1598-9.
136. Dericks-Tan JS, Jost A, Schwedes U, Taubert HD. Pseudohypergonadotropinemia and pseudohyperprolactinemia induced by heterophilic antibodies? Klin Wochenschr 1984;62:265-73.
137. Vladutiu AO, Sulewski JM, Pudlak KA, Stull CG. Heterophilic antibodies interfering with radioimmunoassay. A false-positive pregnancy test. JAMA 1982;248:2489-90.
138. Hellthaler G, Briedigkeit L, Zinn W. Erroneous prolactin determination caused by heterophile antibodies. Geburtsh Frauenheilkd 1995;55:M55-6.
139. Wielaard F, Denissen A, Van Elleswijk-vd Berg J, Van Gemert G. Clinical validation of an antibody-capture anti-rubella IgM-ELISA. J Virol Methods 1985;10:349-54.
140. Sexton SA, Hodgson J, Morgan-Capner P. The detection of rubella-specific IgM by an immunosorbent assay with solid-phase attachment of red cells (SPARC). J Hygiene 1982;88:453-61.
141. Fitzmaurice TF, Brown C, Rifai N, Wu AHB, Yeo K-TJ. False increase of cardiac troponin I with heterophilic antibodies. Clin Chem 1998;44:2212-4.
142. Csako G, Weintraub BD, Zweig MH. The potency of immunoglobulin G fragments for inhibition of interference caused by antiimmunoglobulin antibodies in a monoclonal immunoradiometric assay for thyrotropin. Clin Chem 1988;34:1481-3.
143. Zweig MH, Csako G, Spero M. Escape from blockade of interfering heterophile antibodies in a two-site immunoradiometric assay for thyrotropin. Clin Chem 1988;34:2589-91.
144. Zweig MH, Csako G, Benson CC, Weintraub BD, Kahn BB, Interference by anti-immunoglobulin G antibodies in immunoradiometric assays of thyrotropin involving mouse monoclonal antibodies. Clin Chem 1987;33:840-4.
145. Laurberg P. Persistent problems with the specificity of immunometric TSH assays. Thyroid 1993;3:279-83.
146. Toshima K, Momotani N, Shimizu K, Saito H, Hisaoka T, Yoshimura H, et al. Cases of Graves' disease with falsely high TSH values due to interfering substances which cross-link with mouse monoclonal antibodies in the TSH assay kits. Nippon Naibunpi Gakkai Zesshi Folia Endocrinol Jpn 1993;69:1083-91.
147. Reinhardt W. Thyroid diagnosis: false TSH determination caused by heterophilic antibodies. Dtsch Med Wochenschr 1991;116:1731-2.
148. Brennan MD, Klee GG, Preissner CM, Hay ID. Heterophilic serum antibodies: a cause for falsely elevated serum thyrotropin levels. Mayo Clinic Proc 1987;62:894-8.
149. Bartlett WA, Browning MC, Jung RT. Artifactual increase in serum thyrotropin concentration caused by heterophilic antibodies with specificity for IgG of the family Bovidea. Clin Chem 1986;32:2214-9.
150. Cusick CF, Mistry K, Addison GM. Interference in a two-site immunoradiometric assay for thyrotropin in a child. Clin Chem 1985;31:348-9.
151. Sampson M, Ruddel M, Zweig M, Elin RJ. Falsely high concentration of serum lutropin measured with the Abbott IMx. Clin Chem 1994;40:1976-7.
152. Hiemstra PS, Baldwin WM, van der Voort EA, Paul LC, van Es LA, Daha MR. Polymeric IgA antibody response to rabbit antithymocyte globulin in renal transplant recipients. Transplantation 1988;45:701-5.
153. Vandalem JL, Hennen BG, Czercichow P. Transient apparent hyperthyrotropinemia in mothers and babies [Letter]. Lancet 1980;2:584.
154. Alvarez FV, Scott MG. Interference due to heterophilic antibodies in immunometric assays: you can't win [Abstract]. Clin Chem 1993;39:1268.
155. Kwong PYP, Teale JD. Three cases of erroneous thyroid function tests caused by heterophilic antibodies. Proc ACB Natl Mtg 1994:56.
156. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513-20.
157. Harkiss GD. Antibodies to equine antithymocyte globulin in heart transplant recipients: evaluation of an enzyme immunoassay. J Clin Lab Immunol 1984;15:175-80.
158. Dahlmann N, Bidlingmaier F. Circulating antibodies to mouse monoclonal immunoglobulins caused false-positive results in a two-site assay for alpha-fetoprotein [Letter]. Clin Chem 1989;35:2339.
159. John R, Henley R, Barron N. Antibody interference in a two-site immunometric assay for thyrotrophin. Ann Clin Biochem 1989;26:346-52.
160. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995;55:3060-7.
161. Wieden PL, Wolf SB, Breitz HB, Appelbaum JW, Seller CA, Mallett R, et al. Human anti-mouse antibody suppression with cyclosporin A. Cancer 1994;73:1093-7.
162. Harwood SJ, Camblln JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, et al. Use of technetium antigranulocyte monoclonal antibody Fab′ fragments for the detection of osteomyelitis. Cell Biophys 1994;24-25:99-107.
163. Becker W, Goldeberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med 1994;24:142-53.
164. Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, et al Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Cancer Res 1996;56:1118-25.
165. Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14;461-73.
166. Hosono M, Endo K, Sakanara H, Watenabe Y, Saga T, Nakai T, et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 1992;65:197-200.
167. Kuroki M, Matsumoto Y, Arakawa F, Haruno M, Murakami M, Kuwahara M, et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J Immunol Methods 1995;180:81-91.
168. Otsuji E, Yamaguchi T, Yamaoka N, Kotani T, Kato M, Taniguchi K, et al. Biodistribution of murine and chimeric Fab fragments of the monoclonal antibody A7 in human pancreatic cancer. Pancreas 1995;10:265-73.
169. Gallinger S, Papa MZ, Reilly RM, Xiang J, Kirsh JC, Mullen JB, et al. Comparative biodistribution and antibody-dependent cellular cytotoxicity of native and heavy chain chimeric antibody. Mol Biother 1991;3:197-203.
170. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA, et al. Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab′ fragment by poly(ethyleneglycol) (PEG) modification. Br J Cancer 1996;73:175-82.
171. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
172. Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Targeting 1996;3:321-40.
173. Lang GM, Kierek-Jaszczuk D, Rector ES, Milton AD, Emmrich F, Sehon AH. Suppression of antibody response in rats to murine anti-CD4 monoclonal antibodies by conjugates with monomethoxypolyethylene glycol. Immunol Lett 1992;32:247-52.
174. Beatty JD, Hyams DM, Morton BA, Beatty BG, Williams LE, Yamauchi D, et al. Impact of radiolabeled antibody imaging on management of colon cancer. Am J Surg 1989;157:13-9.
175. Leach JM, Ruck BJ. Detection of Australia antigen by latex agglutination. Aust Patent Spec 1974, 45,020.
176. Nicholson S, Fox M, Epenetos A, Rustin G. Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Int J Biol Markers 1996;11:46-9.
177. Sosolik RC, Hitchcock CL, Becker WJ. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase n a selected patient population. Am J Clin Pathol 1997;107:506-10.
178. Butler J, Sherwood RA. A simple tests for the detection of interference from heterophilic antibodies in immunoassays. Proc Assoc Clin Biochem (UK Natl Mtg) 1995:78.
179. Newman ES, Moskie LA, Duggal RN, Goldenberg DM, Hansen HJ. Murine monoclonal antibody adsorbed onto vinylidene fluoride floccules used to eliminate antibody interference in "sandwich"-type immunoassays. Clin Chem 1989;35:1743-6.
180. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261-4.
181. Schnorr GK, Hachmann H, Harthus HP, Neuenhofer S, Walter G. Interferences of human anti-mouse antibodies in mouse monoclonal antibody based immunoassays [Abstract]. Clin Chem 1989;35:1188.
182. Ferroni P, Milenic DE, Roselli M, Carrasquillo JA, Raubitschek A, Schlom J, Colcher D. Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies. Int J Radiat Appl Instrum Part B 1991;18:383-7.
183. Kaluza B, Lenz H, inventors. Diagnostic test using chimeric antibodies. US patent no. 5,614,367, 1997.
184. Hasholzner U, Stieber P, Meier W, Lamerz R. Value of HAMA - determination in clinical practice - an overview [Review]. Anticancer Res 1997;17:3055-8.
185. Madry N, Auerbach B, Schelp C. Measures to overcome HAMA interferences in immunoassays. Anticancer Res 1997;17:2883-6.